Influence of metabolic syndrome on course of non-alcoholic fatty liver disease


DOI: https://dx.doi.org/10.18565/therapy.2019.3.37-42

Koroy P.V., Slyadnev S.A., Kravchenko Yu.A., Yagoda A.V.

1) Department of hospital therapy of Stavropol State medical University of the Ministry of Healthcare of Russia; 2) Stavropol regional clinical hospital, Department of gastroenterology; 3) Municipal Polyclinic No 9, Stavropol
Objective: clarification of prevalence and influence of metabolic syndrome on course of non-alcoholic fatty liver disease.
Material and methods. Prevalence and influence of metabolic syndrome on features of nonalcoholic fatty liver disease (NAFLD) were studied in 208 patients.
Results and conclusion. The metabolic syndrome present in 59.1 % of cases of NAFLD and it was connected with intensifying of dystrophic and inflammatory changes in liver. Severity of steatosis and inflammation in NAFLD were related with abdominal obesity, insulin resistance, and arterial hypertension. Hepatic fibrosis manifestations were dependent from disorders of tissue sensitivity to insulin and of regulation of blood pressure.
Keywords: non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, metabolic syndrome
Read entire article

Literature


  1. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018; 67(1): 328–57.

  2. Du J., Ma Y.Y., Yu C.H., Li Y.M. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World. J. Gastroenterol. 2014; 20(2): 569–77.

  3. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73–84.

  4. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51(1): 121–29.

  5. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О., Драпкина О.М., Шульпекова Ю.О., Цуканов В.В., Маммаев С.Н., Маев И.В., Пальгова Л.К. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 2: 24–42.

  6. Cotrim H.P., Parise E.R., Oliveira C.P., Leite N., Martinelli A., Galizzi J., Silva Rde C., Mattos A., Pereira L., Amorim W., Ivantes C., Souza F., Costa M., Maia L., Pessoa M., Oliveira F. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann. Hepatol. 2011; 10(1): 33–37.

  7. Chiang D.J., Pritchard M.T., Nagy L.E. Obesity, diabetes mellitus, and liver fibrosis. Am. J. Physiol. Gastrointest. Liver. Physiol. 2011; 300: 697–702.

  8. Chatrath H., Vuppalanchi R., Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin. Liver. Dis. 2012; 32(1): 22–29.

  9. Souza M.R., Diniz Mde F., Medeiros-Filho J.E., Araujo M.S. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq. Gastroenterol. 2012; 49(1): 89–96.

  10. Rivera C.A. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology. 2008; 15: 109–14.

  11. Agrawal R., Mishra S., Dixit V.K., Rai S. Non-alcoholic fatty liver disease and metabolic syndrome. Indian. J. Prev. Soc. Med. 2011; 43(3): 263–66.

  12. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J.The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142(7): 1592–609.

  13. Ghouri N., Preiss D., Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology. 2010; 52: 1156–61.

  14. Smith B.W., Adams L.A. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 2011; 7: 456–65.

  15. Sironi A.M., Sicari R., Folli F., Gastaldelli A. Ectopic fat storage, insulin resistance, and hypertension. Curr. Pharm. Des. 2011; 17: 3074–80.

  16. Lopez-Suarez A., Guerrero J.M., Elvira-González J., Beltran-Robles M., Canas-Hormigo F., Bascunana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur. J. Gastroenterol. Hepatol. 2011; 23(11): 1011–17.

  17. Tarquini R., Lazzeri C., Boddi M., Marra F., Abbate R., Gensini G.F. Non-alcoholic fatty liver disease: a new challenge for cardiologists. G. Ital. Cardiol. (Rome). 2010; 11(9): 660–69.

  18. Latea L., Negrea S., Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. AMJ. 2013; 6(6): 325–30.

  19. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int. J. Cardiol. 2013; 167(4): 1109–17.

  20. Корой П.В., Ягода А.В., Сляднев С.А. Состояние адгезивной функции эндотелия при неалкогольной жировой болезни печени. Врач. 2017; 5: 19–22.

  21. Ягода А.В., Корой П.В., Сляднев С.А. Положительная корреляция уровня молекул суперсемейства иммуноглобулинов ICAM- 1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 138(2): 45–51.

  22. Lucero D., Zago V., Lopez G. I., Graffigna M., Fainboim H., Miksztowicz V., Merono T., Belli S., Levalle O., Wikinski R., Brites F., Berg G., Schreier L. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin. Chim. Acta. 2011; 412(1-2): 143–47.

  23. Bosanska L., Michalsky D., Lacinova Z., Dostalova I., Bartlova M., Haluzikova D., Matoulek M., Kasalicky M., Haluzík M. The influence of obesity and different fat depots on adipose tissue gene expression and protein levels of cell adhesion molecules. Physiol. Res. 2010; 59(1): 79–88.

  24. Tang L., Peng H., Xu T., Wang A., Wang G., Tong W., Zhang Y. Association of biomarkers of inflammation with dyslipidemia and its components among Mongolians in China. PLoS ONE. 2014; 9(2): e89023.

  25. Thompson A.M., Zhang Y., Tong W., Xu T., Chen J., Zhao L., Kelly T.N., Chen C.S., Bazzano L. A., He J. Association of obesity and biomarkers of inflammation and endothelial dysfunction in adults in Inner Mongolia, China. Int. J. Cardiol. 2011; 150(3): 247–52.

  26. Baсun T., Belovari T., Suver M., Dobrosevic B., Glavas-Obrovac L. Effects of hyperglycemia and metformin on expression of adhesion molecules on human aortic endothelial cells. Croatica. Chemica. Acta. 2008; 81(1): 157–62.


About the Autors

Pavel V. Koroy, MD, professor of the Department of hospital therapy of Stavropol State medical University of the Ministry of Healthcare of Russia. Address: 355017, Stavropol, 310 Mira str. Tel.: +7 (865) 271-35-37. E-mail: paule75@yandex.ru
Sergey A. Slyadnev, Doctor of gastroenterology of Stavropol Regional Clinical Hospital.
Address: 355000, Stavropol, 208 Lermontova str. Tel.: +7 (865) 271-32-12. E-mail: bboyscud2011@mail.ru
Yulia A. Kravchenko, therapist of Municipal polyclinic No 9. Address: 355000, Stavropol, 42 Yunosti str.
Tel.: +7 (865) 299-89-89. E-mail: rudenchy@mail.ru
Alexander V. Yagoda, MD, professor, Head of Department of hospital therapy of Stavropol State medical University of the Ministry of Healthcare of Russia, honored worker of science of Russian Federation. Address: 355017, Stavropol, 310 Mira str. Tel.: +7 (865) 229-53-09. E-mail: alexander.yagoda@gmail.com


Similar Articles

Back to Content

Бионика Медиа